Cel-Sci Corporation
In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CVM
Cel-Sci Corporation (CVM) Piotroski F-score
Cel-Sci Corporation's Piotroski F-score for fiscal 2020 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2020 | 4 | — |
How fiscal 2020’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (88.84%) | (77.38%) | Fail | 0 |
| Positive operating cash flow | (15.28m) | (16.32m) | Fail | 0 |
| Rising return on assets | (88.84%) | (77.38%) | Fail | 0 |
| Cash flow above net income | 15.00m | 5.81m | Pass | 1 |
| Falling long-term leverage | 0.34 | 0.47 | Pass | 1 |
| Rising current ratio | 4.15 | 3.25 | Pass | 1 |
| No new shares issued | 1,224,100 | 1,038,100 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.02 | 0.02 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CVM Cel-Sci Corporation | 4 |
| ALGS Aligos Therapeutics, Inc. compare | 3 |
| MGX Metagenomi Therapeutics, Inc. compare | 2 |
| RNAZ TransCode Therapeutics Inc. compare | — |
| BCTX BRIACELL THERAP compare | — |
| GRDX GridAI Technologies Corp. compare | — |
| NXTC NextCure, Inc. compare | — |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | — |
| ATNM Actinium Pharmaceuticals, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover